C4 Therapeutics (CCCC) Assets Average (2020 - 2026)

C4 Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $344.0 million for Q1 2026.

• In Q1 2026, Assets Average rose 2.81% year-over-year to $344.0 million; the TTM figure through Mar 2026 stood at $344.0 million (up 2.81% YoY), while the FY2025 annual figure was $354.3 million, down 2.39% from the prior year.
• Assets Average was $344.0 million for Q1 2026 at C4 Therapeutics, up from $312.3 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $511.1 million in Q1 2022 to a low of $281.0 million in Q3 2025.
• Historically, Assets Average has averaged $385.0 million across 5 years, with a median of $378.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Assets Average soared 32.05% in 2022, then declined 25.78% in 2023.
• A 5-year view of Assets Average shows it stood at $446.1 million in 2022, then declined by 20.49% to $354.7 million in 2023, then increased by 2.28% to $362.8 million in 2024, then decreased by 13.93% to $312.3 million in 2025, then rose by 10.15% to $344.0 million in 2026.
• The last three Assets Average figures came in at $344.0 million (Q1 2026), $312.3 million (Q4 2025), and $281.0 million (Q3 2025), per Business Quant data.